112 related articles for article (PubMed ID: 23327722)
1. Levels of thrombin activatable fibrinolysis inhibitor in gestational diabetes mellitus.
Gumus II; Kargili A; Karakurt F; Kasapoglu B; Derbent A; Kaygusuz I; Koca C; Sevgili S
Gynecol Endocrinol; 2013 Apr; 29(4):327-30. PubMed ID: 23327722
[TBL] [Abstract][Full Text] [Related]
2. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
Akinci B; Demir T; Saygili S; Yener S; Alacacioglu I; Saygili F; Bayraktar F; Yesil S
Diabetes Res Clin Pract; 2008 Jul; 81(1):93-6. PubMed ID: 18406001
[TBL] [Abstract][Full Text] [Related]
3. Plasma thrombin-activatable fibrinolysis inhibitor levels are not associated with glucose intolerance and subclinical atherosclerosis in women with previous gestational diabetes.
Akinci B; Celtik A; Yener S; Genc S; Tunali S; Yuksel F; Ozcan MA; Secil M; Yesil S
Clin Appl Thromb Hemost; 2011; 17(6):E224-30. PubMed ID: 21406417
[TBL] [Abstract][Full Text] [Related]
4. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
Stasko J; Hudecek J; Kubisz P
Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
[TBL] [Abstract][Full Text] [Related]
5. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.
Boffa MB; Koschinsky ML
Clin Biochem; 2007 Apr; 40(7):431-42. PubMed ID: 17331488
[TBL] [Abstract][Full Text] [Related]
6. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy.
Watanabe T; Minakami H; Sakata Y; Matsubara S; Sato I; Suzuki M
Gynecol Obstet Invest; 2004; 58(1):19-21. PubMed ID: 15004439
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.
Alacacioğlu I; Ozcan MA; Alacacioğlu A; Polat M; Yüksel F; Demirkan F; Pişkin O; Ozgenç Y; Ozsan HG; Undar B
Thromb Res; 2004; 114(3):155-9. PubMed ID: 15342211
[TBL] [Abstract][Full Text] [Related]
8. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
Dusse LM; Cooper AJ; Lwaleed BA
Clin Chim Acta; 2007 Mar; 378(1-2):1-6. PubMed ID: 17184758
[TBL] [Abstract][Full Text] [Related]
10. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
Chengwei X; Xiaoli M; Yuan Z; Li P; Shengjiang W; Chao Y; Yunshan W
Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
[TBL] [Abstract][Full Text] [Related]
11. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
12. Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor.
Legnani C; Bovara M; Valdrè L; Cosmi B; Caniato A; Palareti G
Thromb Res; 2012 Aug; 130(2):237-41. PubMed ID: 22032800
[TBL] [Abstract][Full Text] [Related]
13. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
14. A functional assay for measuring activated thrombin-activatable fibrinolysis inhibitor in plasma.
Neill EK; Stewart RJ; Schneider MM; Nesheim ME
Anal Biochem; 2004 Jul; 330(2):332-41. PubMed ID: 15203340
[TBL] [Abstract][Full Text] [Related]
15. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis.
Colucci M; Binetti BM; Branca MG; Clerici C; Morelli A; Semeraro N; Gresele P
Hepatology; 2003 Jul; 38(1):230-7. PubMed ID: 12830006
[TBL] [Abstract][Full Text] [Related]
16. Thrombin activatable fibrinolysis inhibitor: at the nexus of fibrinolysis and inflammation.
Colucci M; Semeraro N
Thromb Res; 2012 Mar; 129(3):314-9. PubMed ID: 22113149
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
18. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.
Kim PY; Foley J; Hsu G; Kim PY; Nesheim ME
Anal Biochem; 2008 Jan; 372(1):32-40. PubMed ID: 17967438
[TBL] [Abstract][Full Text] [Related]
19. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
20. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]